In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast - PubMed (original) (raw)
. 1988 Jan 1;48(1):199-205.
Affiliations
- PMID: 2825967
In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast
R Mariani-Costantini et al. Cancer Res. 1988.
Abstract
We have studied the expression of the c-myc protooncogene and the cycle-dependent histone 4 gene at the cellular level by RNA:RNA in situ hybridization in 18 primary breast ductal adenocarcinomas. These tumors have previously been examined by Southern and Northern blot analysis for the genomic status of c-myc and its expression, respectively (Escot et al., Proc. Natl. Acad. Sci. USA, 83: 4834-4838, 1986). Positive c-myc hybridization signals were associated with carcinoma cells in all cases, including tumors which had no apparent alterations of the c-myc locus. Steady-state levels of c-myc mRNA appeared heterogeneous in carcinomas with similar histology. High levels of hybridization were found in four of seven tumors with strong amplification of the c-myc locus. Similarly high levels of c-myc hybridization were detected in two of nine cases which had an apparently normal c-myc locus but comparatively low cellularity. In addition to carcinoma cells, dense clusters of infiltrating lymphocytes, present in three tumors, exhibited c-myc hybridization. The expression of the histone 4 gene failed to correlate with levels of c-myc expression. We conclude that in infiltrating ductal carcinomas: (a) the c-myc protooncogene is transcriptionally activated; (b) c-myc amplification is probably underestimated due to heterogeneous cellularity; (c) high-level c-myc amplification is related to high-level expression, but other unknown factors also may play a role; (d) differences in levels of c-myc expression may not only be attributed to differences in the growth fractions; and (e) c-myc mRNA in total RNA from biopsy samples may be contributed by infiltrating lymphocytes.
Similar articles
- An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA, Senior PV, Jones JL, Critchley DR, Varley JM. Walker RA, et al. J Pathol. 1989 Jun;158(2):97-105. doi: 10.1002/path.1711580204. J Pathol. 1989. PMID: 2569035 - Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ. Robanus-Maandag EC, et al. J Pathol. 2003 Sep;201(1):75-82. doi: 10.1002/path.1385. J Pathol. 2003. PMID: 12950019 - Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Jimenez RE, et al. Mod Pathol. 2000 Jan;13(1):37-45. doi: 10.1038/modpathol.3880007. Mod Pathol. 2000. PMID: 10658908 - The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
Lavialle C, Modjtahedi N, Lamonerie T, Frebourg T, Landin RM, Fossar N, Lhomond G, Cassingena R, Brison O. Lavialle C, et al. Anticancer Res. 1989 Sep-Oct;9(5):1265-79. Anticancer Res. 1989. PMID: 2686529 Review. - Genomic alterations in human breast cancer: a review.
Mariani-Costantini R, Merlo G, Frati L. Mariani-Costantini R, et al. Tumori. 1989 Aug 31;75(4):311-20. doi: 10.1177/030089168907500404. Tumori. 1989. PMID: 2683275 Review.
Cited by
- Genetic alterations in primary breast cancer.
Callahan R. Callahan R. Breast Cancer Res Treat. 1989 Jul;13(3):191-203. doi: 10.1007/BF02106570. Breast Cancer Res Treat. 1989. PMID: 2667653 Review. - Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.
Tyner JW. Tyner JW. Ther Adv Hematol. 2011 Apr;2(2):83-93. doi: 10.1177/2040620711403028. Ther Adv Hematol. 2011. PMID: 23556079 Free PMC article. - Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas.
Münzel P, Marx D, Köchel H, Schauer A, Bock KW. Münzel P, et al. J Cancer Res Clin Oncol. 1991;117(6):603-7. doi: 10.1007/BF01613296. J Cancer Res Clin Oncol. 1991. PMID: 1683873 - The MYC oncogene is a global regulator of the immune response.
Casey SC, Baylot V, Felsher DW. Casey SC, et al. Blood. 2018 May 3;131(18):2007-2015. doi: 10.1182/blood-2017-11-742577. Epub 2018 Mar 7. Blood. 2018. PMID: 29514782 Free PMC article. Review. - Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.
Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML. Miliani de Marval PL, et al. Mol Cell Biol. 2004 Sep;24(17):7538-47. doi: 10.1128/MCB.24.17.7538-7547.2004. Mol Cell Biol. 2004. PMID: 15314163 Free PMC article.
MeSH terms
LinkOut - more resources
Medical